Taken together, these results suggest that the selection and prioritization of patients for clinical trials should consider the patient's age, the RP form according to the fundus appearance, the presence of high myopia, as well as the localization and type of causative variants in the RPGR gene. Here, RPGR is linked to retinitis pigmentosa 1.